Version:

02-04-2014 23-10-2014: Recommendation for vaccination against invasive meningococcal disease 08-02-2016: Recommendation for pertussis vaccination in pregnancy 07-06-2017: Adult vaccination schedule changes 01-01-2018: Change to the primary immunisation schedule 01-09-2019: Gender-neutral HPV introduced 04-11-2021: Updated recommendations for COVID-19 Vaccine 01-01-2022: 01 Jan 2022: updated recommendations for meningococcal vaccination 01-01-2023: 2023 vaccination calendar 01-01-2024: 2024 vaccination calendar 15-04-2024: April 2024 version

Footnotes:

1. For specific risk groups vaccination is covered by the health insurance.
2. Vaccination of one dose against measles for those aged 18 years and above who are newly admitted to work on an infectious or dermatovenerological ward (mandatory vaccination)
3. https://koronavirus.mzcr.cz/ockovani-proti-covid-19/
4. Administered from 4th day until 6 weeks after birth. Given only to babies in at-risk groups.
5. Recommended only. Vaccination not funded by the National Health system or health insurance.
6. The first dose of hexavalent vaccine is given from the end of the 2nd month of life, at intervals of two months between the first and the second dose, and the third dose given between the eleventh and thirteenth months of the child's age
7. Booster dose for person between 25th and 26th years of age; next booster dose every 10 - 15 years
8. One booster dose in adulthood is recommended, 10 to 15 years after the last dose. Pertussis vaccination is also recommended for pregnant women from the 27th gestational week. Vaccination is recommended at every pregnancy.
9. Babies born to HBsAg-positive mothers will be given a first dose within 24 hours after birth by law
10. 3 doses. if susceptible and no history of vaccination. mandatory for specific at risk groups
11. Any PCV or PPSV23. Vaccination is especially recommended for people with chronic lung disease (includes moderate and severe bronchial asthma), with long-term medical treatment; persons with heart disease and/or large vessels with long-term systemic medical treatment, such as hypertension; people with chronic kidney and liver disease; patients with diabetes mellitus; patients with an immune disorder system (eg patients with immunosuppressive treatment (steroids, HIV infections, etc.) and asplenia / hyposplenia; patients with anticancer treatment; patients before / after solid organ and / or bone marrow transplantation; people with severe obesity (BMI over 40 kg / m2) and persons over 65 years of age.
12. 1.Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. 3. Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
13. 1.Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. 3. Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
14. MenB 1.Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. 3. Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. MCV4 1.Vaccination with MCV4 vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for toodlers with MCV4 vaccine is covered by health insurance since May 2020 if is administered at the age interval from 12 to 23 months. 3.Vaccination for adolescents with MCV4 vaccine is covered by health insurance since January 2022 if is administered at the age interval from 14 to 16 years. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
15. MenB 1.Vaccination with MenB vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for small infants with MenB is covered by health insurance since May 2020 if the schedule is started before the age of 1 year. 3. Vaccination for adolescents with MenB vaccine is covered by health insurance since January 2022 if vaccination is started at the age interval from 14 to 16 years. MCV4 1.Vaccination with MCV4 vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination for toodlers with MCV4 vaccine is covered by health insurance since May 2020 if is administered at the age interval from 12 to 23 months. 3.Vaccination for adolescents with MCV4 vaccine is covered by health insurance since January 2022 if is administered at the age interval from 14 to 16 years. More details of the recommendation is available at: https://szu.cz/wp-content/uploads/2024/01/2024-Recommendation-for-vaccination-against-IMD.pdf
16. catch-up for are newly admitted to work on an infectious or dermatovenerological ward
17. Gender-neutral (boys and girls) vaccination recommended since September 2019. Vaccination is covered by health insurance for all 13-14-year old. 2 and 4 valent vaccine.
18. For at-risk groups of any age. Recommended only. The vaccination is covered by the health insurance. In addition, there is a general recommendation for whole population. This vaccination is not covered by the health insurance.
19. General recommendation for all population. 2 doses, if susceptible and no history of vaccination. Mandatory for specific at-risk groups. Vaccination not funded by the National Health system except at-risk groups.
20. 5 doses post-exposure, 3 doses pre-exposure
21. 3 doses, re-vaccination every 5 years. Recommended only. Vaccination not funded by the National Health system.

More information available at:
https://www.vzp.cz/pojistenci/prevence/ockovani https://szu.cz/temata-zdravi-a-bezpecnosti/vakciny-a-ockovani/informace-o-infekcich-v-ramci-ockovani-v-cr-i/ https://szu.cz/tema/vakciny-a-ockovani/ockovaci-kalendar-v-cr/


_______________________________________________________________________


HISTORICAL CHANGES:
1946: Diphteria vaccination introduced into the national childhood vaccination schedule
1952: Tetanus vaccination administered to children in communities
1953: TB vaccination introduced into the national childhood vaccination schedule
1956: Tetanus vaccination introduced into the national childhood vaccination schedule
1958: WCP vaccination introduced into the national childhood vaccination schedule
1960-1969: Oral polio vaccination present in the national childhood vaccination schedule
1969: Measles vaccination for babies at 12 months of age introduced into the national childhood vaccination schedule
1982: Measles – two dose vaccination regime administered to children at 15 months of age and 6-10 months after receiving the first dose
1982: Rubella vaccination for 12 year old girls introduced into the national childhood vaccination schedule
1986: Rubella vaccination for children at 2 years of age introduced into the national childhood vaccination schedule
1987: Mumps vaccination for babies at 15 months introduced into the national childhood vaccination schedule
2001: Hib vaccination introduced into the national childhood vaccination schedule and administered to all children in the first year of life
2001: HepB vaccination introduced into the national childhood vaccination schedule and administerd to all children in the 1st and 12th year of life
2007: IPV replaced OPV in the 1st year of life
2007: Acellular pertussis vaccine (aP) replaced the whole-cell vaccine (wP) in the 1st year of life
2010: Recommended PCV vaccination for babies in their 1st year of life introduced in the national vaccination schedule
2014: Updated recommendation for recommendation for vaccination against invasive meningococcal disease
2016: Pertussis vaccination during pregnancy introduced
2018: Change to the primary infant schedule from a 3+1 to 2+1 scheme in the first year of life
2019: Gender-neutral HPV vaccination



_______________________________________________________________________


VACCINATION FOR PREGNANT WOMEN
http://www.mzcr.cz/Verejne/dokumenty/doporuceni-narodni-imunizacni-komisenikopro-ockovani-tehotnych-zen-proti-per_11107_1985_5.html


_______________________________________________________________________


VACCINATIONS RECOMMENDED FOR AT-RISK GROUPS:
Healthcare workers: pertussis- recommended only - one booster dose should include pertussis (Td-acp); Hepatitis B - mandatory by law
Employees of Integrated Rescue System: Hepatitis A and B - mandatory by law
Military and judicial guard, social workers: Hepatitis B - mandatory by law
Laboratories working with virulent strains of rabies: Rabies - mandatory by law, revaccination after 2-5 years
Babies/children: pneumococcal disease for children at risk - mandatory by law; hepatitis B for children of HBsAg-positive mothers


_______________________________________________________________________


Date of last update: 15 April 2024.